IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Apellis Pharmaceuticals Inc (APLS)

CUSIP: 03753U106 | NYSE | Healthcare · Biotechnology | Mid Cap | 854 institutional holders

Quarters

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13D/ABiogen Inc.00.0%Fell below 5%May 14, 2026No 13F filer matched
13D/ABiogen Inc.0
0.0% of class · May 14, 2026Fell below 5%
No 13F filer matched

Institutional Holders — Q2 2026

IFP Advisors, Inc248
0.0% of portfolio›$10.2K
StyleTurnoverLocationFiled
IFP Advisors, Inc
248$10.2K0.0%GrowthLowTampa, FL2026-07-20